High prevalence of Mycoplasma genitalium infection and macrolide resistance in patients enrolled in HIV pre-exposure prophylaxis program.

AIDS-Related Opportunistic Infections / drug therapy Adult Anti-Bacterial Agents / therapeutic use Drug Resistance, Bacterial Female Follow-Up Studies HIV HIV Infections / complications Humans Macrolides / therapeutic use Male Mycoplasma Infections / drug therapy Mycoplasma genitalium / drug effects Pre-Exposure Prophylaxis / methods Prevalence Sexual and Gender Minorities / statistics & numerical data Transgender Persons / statistics & numerical data Treatment Failure
Macrolides Mycoplasma genitalium Pre-exposure prophylaxis Prophylaxie pré-exposition

Journal

Medecine et maladies infectieuses
ISSN: 1769-6690
Titre abrégé: Med Mal Infect
Pays: France
ID NLM: 0311416

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 15 05 2018
revised: 26 06 2018
accepted: 05 03 2019
pubmed: 28 3 2019
medline: 21 1 2020
entrez: 28 3 2019
Statut: ppublish

Résumé

Limited data on Mycoplasma genitalium infection has been reported among PrEP users. The aim of this study was to estimate the prevalence and macrolide resistance of M. genitalium infection among enrollees in a French PrEP program. M. genitalium infection screening was systematically and prospectively proposed to patients of the Bordeaux PrEP program (between January 2016 and February 2017). Macrolide resistance was evaluated in M. genitalium-positive patients. Among 89 clients, M. genitalium infection prevalence was 10% (mainly asymptomatic) with a high rate of macrolide resistance (58%). Because of a high level of macrolide resistance, a systematic search for M. genitalium macrolide resistance associated-mutations may be recommended in PrEP users before initiating the antibiotic therapy.

Identifiants

DOI: 10.1016/j.medmal.2019.03.007 PMID: 30914213
pubmed: 30914213
pii: S0399-077X(18)30660-7
doi: 10.1016/j.medmal.2019.03.007
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Macrolides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

347-349

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

M Deborde (M)

Infectious and tropical diseases department, Pellegrin hospital, Bordeaux university hospital, 33000 Bordeaux, France.

S Pereyre (S)

USC EA 3671, Mycoplasma and chlamydia human infections, Bordeaux university, 33000 Bordeaux, France; USC EA 3671, Mycoplasma and chlamydia human infections, French National Institute for Agricultural Research, 33000 Bordeaux, France; Bacteriological laboratory, Bordeaux university hospital, 33000 Bordeaux, France.

M Puges (M)

Infectious and tropical diseases department, Pellegrin hospital, Bordeaux university hospital, 33000 Bordeaux, France.

C Bébéar (C)

USC EA 3671, Mycoplasma and chlamydia human infections, Bordeaux university, 33000 Bordeaux, France; USC EA 3671, Mycoplasma and chlamydia human infections, French National Institute for Agricultural Research, 33000 Bordeaux, France; Bacteriological laboratory, Bordeaux university hospital, 33000 Bordeaux, France.

A Desclaux (A)

Infectious and tropical diseases department, Pellegrin hospital, Bordeaux university hospital, 33000 Bordeaux, France.

M Hessamfar (M)

Inserm U1219 - Bordeaux population health, institute for public health, epidemiology, and development (ISPED), Bordeaux university, 33000 Bordeaux, France; COREVIH Aquitaine, Bordeaux university hospital, 33000 Bordeaux, France; Infectious diseases and internal medicine department, Saint-André hospital, Bordeaux university hospital, 33000 Bordeaux, France.

C Le Roy (C)

USC EA 3671, Mycoplasma and chlamydia human infections, Bordeaux university, 33000 Bordeaux, France; USC EA 3671, Mycoplasma and chlamydia human infections, French National Institute for Agricultural Research, 33000 Bordeaux, France.

F Le Marec (F)

Inserm U1219 - Bordeaux population health, institute for public health, epidemiology, and development (ISPED), Bordeaux university, 33000 Bordeaux, France.

F Dabis (F)

Inserm U1219 - Bordeaux population health, institute for public health, epidemiology, and development (ISPED), Bordeaux university, 33000 Bordeaux, France; COREVIH Aquitaine, Bordeaux university hospital, 33000 Bordeaux, France.

C Cazanave (C)

Infectious and tropical diseases department, Pellegrin hospital, Bordeaux university hospital, 33000 Bordeaux, France; USC EA 3671, Mycoplasma and chlamydia human infections, Bordeaux university, 33000 Bordeaux, France; USC EA 3671, Mycoplasma and chlamydia human infections, French National Institute for Agricultural Research, 33000 Bordeaux, France. Electronic address: charles.cazanave@chu-bordeaux.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Infections opportunistes liées au SIDA › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance bactérienne aux médicaments › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Polycétides › Macrolides › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram négatif › Infections à Mycoplasmatales › Infections à Mycoplasma › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Bactéries › Bactéries à Gram négatif › Tenericutes › Mycoplasmatales › Mycoplasmataceae › Mycoplasma › Mycoplasma genitalium › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Prophylaxie pré-exposition › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Personnes › Disparités en matière de santé, minorités et populations vulnérables › Minorités sexuelles › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Personnes › Disparités en matière de santé, minorités et populations vulnérables › Minorités sexuelles › Personnes transgenres › High prevalence of Mycoplasma genitalium...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Échec thérapeutique › High prevalence of Mycoplasma genitalium...